Clinical Trial Update: Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing two gliclazide 80 mg tablet formulations in healthy volunteers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Gliclazide 80 mg tablet (Formulation A) (Gliclazide)
• Gliclazide 80 mg tablet (Formulation B) (Gliclazide)

Snippet

Sponsor: Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited | Conditions: Healthy | Phase 1 | Status: COMPLETED